studies

breast cancer (BC), trastuzumab based treatment vs. HER2 inhibitor, meta-analysis of study results

OutcomeTE95% CInkI2ROBPub. bias deaths (OS)detailed resultsCLEOPATRA, 2012 0.66 [0.52; 0.84] HER2CLIMB, 2020 0.66 [0.50; 0.88] SYSUCC-002, 2022 0.82 [0.65; 1.04] 0.72[0.62; 0.83]CLEOPATRA, 2012, HER2CLIMB, 2020, SYSUCC-002, 202232%1,812lownot evaluable deaths (OS) (extension)detailed resultsCLEOPATRA, 2012 0.69 [0.58; 0.82] 0.69[0.58; 0.82]CLEOPATRA, 201210%808NAnot evaluable PFS (extension)detailed resultsCLEOPATRA, 2012 0.69 [0.59; 0.81] 0.69[0.59; 0.81]CLEOPATRA, 201210%808NAnot evaluable progression or deaths (PFS)detailed resultsCLEOPATRA, 2012 0.62 [0.51; 0.75] HER2CLIMB, 2020 0.54 [0.42; 0.70] HER2CLIMB (patients with brain metastases), 2020 0.48 [0.34; 0.68] SYSUCC-002, 2022 0.88 [0.71; 1.09] 0.63[0.49; 0.81]CLEOPATRA, 2012, HER2CLIMB, 2020, HER2CLIMB (patients with brain metastases), 2020, SYSUCC-002, 2022476%1,971lownot evaluable objective responses (ORR)detailed resultsCLEOPATRA, 2012 10.80 [5.29; 22.05] 10.80[5.29; 22.05]CLEOPATRA, 201210%679NAnot evaluable AE leading to treatment discontinuation (any grade)detailed resultsHER2CLIMB, 2020 1.92 [0.77; 4.80] 1.92[0.77; 4.80]HER2CLIMB, 202010%601NAnot evaluable0.220.01.0relative treatment effectwww.metaEvidence.org2024-07-01 14:57 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 64,370,336,147,145,355,337,146,317,4,319,144,356,351,357,352,354,353,358,359,324,142,305,306,98,96,269,60,143,270,140,240,3 - treatments: 1299,1334,1332,1303,1325,1320,1305,1300,1429,1324,1335,1307,1322

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons